GFC Life Science지에프씨생명과학

GFC Life Science shows a small TTM profit on ₩19.2B revenue, but its shares have fallen about 75% over the past year and free cash flow is negative.

GFC Life Science makes cosmetic ingredients and runs a clinical testing division that supports cosmetic claims. Trailing twelve-month revenue is ₩19.2B with operating income of ₩841M and net income of ₩1.08B as of H1 2026, after a large net loss of ₩5.9B in 2024. The share price closed at ₩4,480 on 2026-10-28, well below its 52-week high of ₩18,570.

What stands out

• Revenue grew 5.4% in 2025 to ₩17.7B, but operating margin fell from 10.1% in 2024 to 2.2% in 2025 and was 4.4% on a trailing basis.
• Net income is positive on a trailing basis, but the 2024 net loss of ₩5.9B and a 2025 ROE of 3.2% show earnings have been unstable.
• Free cash flow is negative at about ₩6.9B on a trailing basis, while borrowings of ₩9.2B exceed cash of ₩6.6B.
• Foreign ownership fell from 3.0% to 2.6% over the past 60 days, and retail and institutional investors were net sellers over the last 20 days.
• Recent headlines cover export deals for the fmk cosmetics brand in Vietnam and Italy and a K-Beauty Expo product selection. Filings include an asset revaluation and a shareholder meeting.

What to watch

• Next periodic results and whether operating margin recovers from the trailing 4.4% level.
• Free cash flow and the ₩9.2B borrowings position, which the data shows as larger than cash.
• Outcome and details of the asset revaluation and the frequent insider and 5%+ holding reports; the data does not explain their purpose.